ZIA CP005804-10105 (ZIA) | |||
---|---|---|---|
Title | PLCO - Lung | ||
Institution | NCI, Bethesda, MD | ||
Principal Investigator | Caporaso, Neil | NCI Program Director | N/A |
Cancer Activity | N/A | Division | DCEG |
Funded Amount | $11,023 | Project Dates | 00/00/0000 - 00/00/0000 |
Fiscal Year | 2017 | Project Type | Intramural |
Research Topics w/ Percent Relevance | Cancer Types w/ Percent Relevance | ||
Biochemical Epidemiology (45.0%) Cancer (100.0%) Smoking Behavior (34.0%) |
Lung (100.0%) | ||
Research Type | |||
Interactions of Genes and/or Genetic Polymorphisms with Exogenous and/or Endogenous Factors Population-based Behavioral Factors |
|||
Abstract | |||
"This study evaluates etiology for lung cancer and related diseases (e.g. COPD/emphysema) among screening arm participants in the PLCO Trial, a randomized control trial to evaluate the effectiveness of screening for prostate, lung, colorectal and ovarian cancer. The study includes about 75,000 subjects, aged 55-74 years, recruited at 10 U.S. Screening Centers. The study is identifying risk factors for smoking behavior, lung cancer and related diseases. Currently, we have evaluated a panel of genetic polymorphisms involving genes controlling pathways related to nicotine or neurotransmitters (dopamine, serotonin) that may be related to the smoking phenotype. This analysis involved 1000 current and 1000 former smokers, matched on age, gender, and smoking intensity. We will be able to isolate selected subpopulations of smokers for special study, including heavy smokers (i.e., intensity greater than 20 cigarettes per day) and chippers (fewer than 5 cigarettes per day). Obesity, medical conditions related to tobacco use (emphysema, bronchitis, other cardiac and respiratory conditions) and alcohol intake will be taken into account in the analysis. Additional analyses are planned involving genetics of smoking, alcohol use, COPD, inflammation and inflamatory markers, CXR results. In some cases these findings will be combined with results from other lung cancer studies such as EAGLE and other cohorts including ATBC. We also work with lung cancer consortia to further extend findings from PLCO. " |